T–CELL VACCINE PREPARATION FOR MULTIPLE SCLEROSIS TREATMENT
https://doi.org/10.15789/1563-0625-2005-1-27-32
Abstract
Abstract. A two–stage technology of preparation of T–cell vaccine designated for multiple sclerosis treatment is described. At the first stage myelin–specific lymphocytes undergoe antigen–dependent cultural selection, whereas at the second stage they are grown by means of non–specific stimulation. The vaccine prepared in this way was found to induce specific anti–idiotypic immune response, directed against myelin–reactive T–lymphocytes. The results of 1–year follow–up of 18 vaccinated patients with a cerebral–spinal type of multiple sclerosis indicated the absence of side effects of T–cell vaccination, and suggest the possibility of effective application of this treatment within early stages of disease. (Med. Immunol., 2005, vol.7, № 1, pp 27532)
About the Authors
I. P. Ivanova
ГУ НИИ клинической иммунологии СО РАМН, г. Новосибирск
Russian Federation
Russian Federation
V. I. Seledzov
ГУ НИИ клинической иммунологии СО РАМН, г. Новосибирск
Russian Federation
Russian Federation
N. V. Banul
ГУ НИИ клинической иммунологии СО РАМН, г. Новосибирск
Russian Federation
Russian Federation
D. M. Samarin
ГУ НИИ клинической иммунологии СО РАМН, г. Новосибирск
Russian Federation
Russian Federation
G. V. Seledzova
ГУ НИИ клинической иммунологии СО РАМН, г. Новосибирск
Russian Federation
Russian Federation
I. V. Savkin
ГУ НИИ клинической иммунологии СО РАМН, г. Новосибирск
Russian Federation
Russian Federation
V. S. Shyrinsky
ГУ НИИ клинической иммунологии СО РАМН, г. Новосибирск
Russian Federation
Russian Federation
N. V. Pronkina
ГУ НИИ клинической иммунологии СО РАМН, г. Новосибирск
Russian Federation
Russian Federation
V. A. Kozlov
ГУ НИИ клинической иммунологии СО РАМН, г. Новосибирск
Russian Federation
Russian Federation
References
1. Chou Y.K, Boudete D.N., Offner H. Frequency of T cells specific for myelin basic protein and myelin pro teolipid protein in blood and cerebrospinal fluid in mul tiple sclerosis // J.Neuroimmunol. — 1992. — Vol.38, № 1 2. — P.105—113.
2. Correale J., Lund B., McMillan M. T–cell vaccination in secondary progressive multiple sclerosis // J.Neuroimmunol. — 2000. — V.107, №2. — P. 130—139.
3. Deibler G.E., Martenson R.E. and Kies M.W. Large scale preparation of myelin basic protein of several mammalian species // Prep. Biochem. — 1972. — №2. — P.139—165.
4. Hohlfeld R. Biotechnological agents for the immunotherapy of multiple sclerosis // Brain. — 1997. — V.120. — P. 865—916.
5. Hermans G., Medaer R., Raus J., Stinissen P. Myelin reactive T cells after T cell vaccination in multiple sclerosis: cytokine profile and depletion by additional immunizations // J.Neuroimmunol. — 2000. — V.102, №1. — P.79–84.
6. Мor F., Cohen I.R. Experimental aspects of T cell vaccination // Clin. Exp. Rheumatol. — 1993. — Suppl.8. — P.55–57.
7. Pender M.P., Csurhes P.A., Greer J.M. Surges of increased T cell reactivity to an encephalitogenic region of myelin proteolipid protein occur more often in patients with multiple sclerosis than in healthy subjects // The Journal of Immunology. — 2000. — V.165, № 9. — Р. 5322–5331.
8. Pette M., Fujita K., Kitze B. Myelin basic protein specific T lymphocyte lines from MS patients and healthy individuals // Neurology. — 1990. — V. 40, №11. — P. 1770–1776.
9. Stinissen P., Zhang J., Medaer R. Vaccination with autoreactive T cell clones in multiple sclerosis: overeiew of immunological and clinical data // J. of Neuroscience Research. — 1996. — V.45. — P.500–511.
10. Stinissen P. and Raus J. Autoreactive T lymphocytes in multiple sclerosis: pathogenic role and therapeutic targeting // Acta neurol. Belg. — 1999. — V.99. — P.65–69.
11. Sun J.–B. Autoreactive T and B cells in nervous system diseases // Acta neurol. Scandinavica. — 1993. — V. 87, №142. — Suppl. — P.5–56.
12. Zang Y.C.Q., Hong J., Tejada–Simon M.V. Th 2 immune regulation induced by T cell vaccination in patients with multiple sclerosis // Eur. J.Immunol. — 2000. — V.30. — P. 908–913.
13. Zhang J., Stinissen P., Medaer R. Т cell vaccination: clinical application in autoimmune diseases // J.Mol.Med. — 1996. — V. 74. — P. 653–662.
Review
For citations:
Ivanova I.P., Seledzov V.I., Banul N.V., Samarin D.M., Seledzova G.V., Savkin I.V., Shyrinsky V.S., Pronkina N.V., Kozlov V.A. T–CELL VACCINE PREPARATION FOR MULTIPLE SCLEROSIS TREATMENT. Medical Immunology (Russia). 2005;7(1):27-32. (In Russ.) https://doi.org/10.15789/1563-0625-2005-1-27-32
Views:
2305
Email this article 